{"entity":{"id":"nct07811193","kind":"trial","name":"A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum","aka":[],"tldr":"A phase 2 trial of Pembrolizumab in colorectal cancer, run by Vividion Therapeutics, Inc., now recruiting.","summary":"A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum is a phase 2 interventional study registered as NCT07811193 by Vividion Therapeutics, Inc., with 140 participants planned, started 2026-09-11 and due to reach its primary completion in 2028-06-30. Interventions recorded: VVD-133214 and Pembrolizumab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07811193","url":"https://clinicaltrials.gov/study/NCT07811193"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":["bayer"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07811193","phase":"2","setting":"A Phase 2, Randomized, Open-label Study of VVD-133214 in COmbination With Pembrolizumab Compared to Pembrolizumab Monotherapy in Participants With Advanced Colorectal Adenocarcinoma (CRC) Harboring Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (DMMR)","sponsor":"Vividion Therapeutics, Inc.","enrolled":140,"outcomes":[]},"route":"/trials/nct07811193/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"bayer","kind":"company","name":"Bayer","route":"/companies/bayer/"}]}}